BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/31/2015 10:55:00 AM | Browse: 1211 | Download: 1227
 |
Received |
|
2014-07-01 09:34 |
|
Peer-Review Started |
|
2014-07-01 13:55 |
|
To Make the First Decision |
|
2014-09-28 14:00 |
|
Return for Revision |
|
2014-09-29 17:39 |
|
Revised |
|
2014-10-23 22:35 |
|
Second Decision |
|
2014-11-12 13:53 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2014-11-19 11:09 |
|
Articles in Press |
|
2014-11-19 11:10 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-03-26 19:08 |
|
Publish the Manuscript Online |
|
2015-03-31 10:28 |
| ISSN |
2219-2824 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Review |
| Article Title |
Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mira A Patel, Jennifer E Kim, Jacob Ruzevick and Michael Lim |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Michael Lim, MD, Associate Professor of Neurosurgery and Oncology, Department of Neurosurgery, the Johns Hopkins University School of Medicine, 600 N. Wolfe St., Phipps Building Rm 123, Baltimore, MD 21287, United States. mlim3@jhmi.edu |
| Key Words |
Programmed death-1; Cytotoxic T lymphocyte associated antigen-4; Ipilimumab; Nivolumab; Immune checkpoint |
| Core Tip |
Aggressive cancer growth is often characterized by tumor expression of molecules that co-opt effective immune responses through immune checkpoints. Clinical blockade of checkpoints programmed death-1 and cytotoxic T lymphocyte associated antigen-4 and has spurred the discovery of a number of immune checkpoints that may be inhibited in anticancer therapy. The clinical successes of checkpoint blockade have led to increasing interest in combining treatment modalities. Combination checkpoint blockade with chemoradiation has shown synergistic effects, and checkpoint blockade with bacterial vaccine vectors have produced increased immune responses in pre-clinical models. The future of immune checkpoint blockade may be as a powerful adjuvant alongside the current standard of care. |
| Publish Date |
2015-03-31 10:28 |
| Citation |
Patel MA, Kim JE, Ruzevick J, Lim M. Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches. World J Immunol 2015; 5(1): 1-15 |
| URL |
http://www.wjgnet.com/2219-2824/full/v5/i1/1.htm |
| DOI |
http://dx.doi.org/10.5411/wji.v5.i1.1 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
